STING1 and neoplasm: While our results regarding therapeutic anti-tumor synergy between STING agonists and individual ARGi, COX2i, or ICI treatments are consistent with some previous reports (11, 29–34), they reinforce a critical need to consider intrinsic heterogeneity in tumors and their associated TMEs as important variables in estimating the likely efficacy of specific drug combinations in STING-based immunotherapies.